Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma

Clinical trials in cancer
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory BCMA/TACI positive relapsed and/or refractory multiple myeloma. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.

Share This Post

Brief Summary:

A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma

 

Detailed Description:

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory BCMA/TACI positive relapsed and/or refractory multiple myeloma. The selection of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. The primary objective is to explore safety; the main consideration is dose-related safety.

 

Criteria

Inclusion Criteria:

  1. Histologically confirmed diagnosis of BCMA/TACI+ multiple myeloma (MM):
    1. Patients with MM who relapsed after BCMA CAR-T therapy; Or MM with positive BCMA/TACI expression;
    2. Relapsed after hematopoietic stem cell transplantation;
    3. Cases with recurrent positive minimal residual disease;
    4. Extramedullary lesion, which is hard to eradicate by chemotherapy or radiotherapy.
  2. Male or female aged 18–75 years;
  3. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;
  4. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
  5. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
  6. Estimated survival time ≥ 3 months;
  7. ECOG performance status 0 to 2;
  8. Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.

Exclusion Criteria:

Subjects with any of the following exclusion criteria were not eligible for this trial:

  1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;
  2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
  3. Pregnant (or lactating) women;
  4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
  5. Active infection of hepatitis B virus or hepatitis C virus;
  6. Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids;
  7. Previously treated with any CAR-T cell product or other genetically modified T cell therapies;
  8. Creatinine > 2.5 mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin > 2.0 mg/dl;
  9. Other uncontrolled diseases that were not suitable for this trial;
  10. Patients with HIV infection;
  11. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟